# Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

> **NCT03229278** · PHASE1 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Metastatic Renal Cell Cancer
- Recurrent Bladder Carcinoma
- Recurrent Classical Hodgkin Lymphoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Recurrent Lymphoma
- Recurrent Malignant Solid Neoplasm
- Recurrent Renal Cell Carcinoma
- Stage III Bladder Cancer
- Stage III Lymphoma
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage III Renal Cell Cancer
- Stage III Skin Melanoma
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIA Skin Melanoma
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Skin Melanoma
- Stage IIIC Skin Melanoma
- Stage IV Bladder Cancer
- Stage IV Lymphoma
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Stage IV Renal Cell Cancer
- Stage IV Skin Melanoma
- Stage IVA Bladder Cancer
- Stage IVB Bladder Cancer
- Unresectable Head and Neck Squamous Cell Carcinoma
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** Enzyme Inhibitor Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03229278
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-03
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229278, "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03229278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*